Favoritism at best - Clinical Research Manager bei Merck: Mitarbeiterbewertung

2,0
17. März 2022
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

If you belong to a certain ethnic group, or if you are known by the leadership group then you are in line for promotion or for opportunities.

Kontras

No opportunities to grow. No career path for Clinical Research Managers. Only Study Managers, COMs and CRAs have career paths. You need to be a Director or VP ‘favorite’ to be considered for opportunities to grow or promotions. Positions are created only for the favorites or for certain ethnic backgrounds. Only favorites are rewarded. Multiple systems are used, systems don’t talk to each other. CRMs are expected to manage projects, go to sites to do CRA work, conduct quality visits, evaluation visits and initiation visits. Also, CRMs are expected to volunteer in company initiatives. CRMs do the job for 2-3 people but are only paid for 1 person. CRMs have to do what directors, CRAs and Study Managers don’t want to do. CRMs have to complete multiple trackers because other people can’t run reports from the systems. No support from Monitoring Management. If there are issues with CRAs you are expected to call the line manager to address the situation. CRAs are protected by their managers even those who don’t perform. CRMs are told to be careful with CRAs as the company is struggling with CRAs leaving the organization. Salary is not aligned with inflation, other companies are offering more. The vendor (CRO) manages the sponsor. Stay away from this company!

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle